FTSE MIB
25.954,67 -527,54 (-1,99%) Dow Jones
31.913,53 -191,72 (-0,60%) Nasdaq
11.725,45 -61,95 (-0,53%) Nikkei 225
27.385,25 -34,36 (-0,13%) Petrolio
68,08 -1,88 (-2,69%) Bitcoin EUR
25.842,49 +391,54 (+1,54%)
BYD Sep 2023 65.000 call
| Chiusura precedente | 4,8000 |
| Aperto | 4,8000 |
| Denaro | 3,2000 |
| Lettera | 4,8000 |
| Prezzo d'esercizio | 65,00 |
| Scadenza | 2023-09-15 |
| Min-Max giorno | 4,8000 - 4,8000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 154 |
- GlobeNewswire
Gaming and Leisure Properties, Inc. Reports Record Fourth Quarter Results, Establishes 2023 Guidance and Announces 2023 First Quarter Dividend of $0.72 per Share and Special Dividend of $0.25 per Share
WYOMISSING, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) (“GLPI” or the “Company”) today announced record results for the fourth quarter and year-ended December 31, 2022. Financial Highlights Three Months Ended December 31,Year Ended December 31, (in millions, except per share data) 2022 Actual 2021 Actual2022 Actual 2021 Actual Total Revenue $336.4 $298.3$1,311.7 $1,216.4 Income From Operations $275.5 $204.4$1,029.9 $841.8 Net income $199.6 $119.6$70
- GlobeNewswire
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease. Simufilam is Cassava Sciences’ lead drug candida
